Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. “As we close out the first quarter of 2 ...

PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025."Our strategic focus remains on advancing our clinical programs, and we anticipate several significant development milestones. These include top-line resul ...

Theravance Biopharma (TBPH) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Rick Winningham - CEORhonda Farnum - Chief Business Officer and Senior VP of Commercial & Medical AffairsAziz Sawaf - SVP - Operations & Strategy and CFOAine Miller - SVP - Development & Head of Ireland Office Conference Call Participants Marc Frahm - AnalystNone - Analyst Operator Hello, ladies and gentlemen. Good afternoon. I would like to welcome everyone to the Theravance Biopharma First Quarter twenty twenty ...

Q1 2025 Results This presentation is intended for the investor community only; it is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. All trademarks in this presentation are the property of their respective owners. This presentation includes U.S. generally accepted accounting principles ("GAAP") and non-GAAP financial measures. Reconciliations between these two measures are provided in the appendix to this presentation. Some of the clinical data ...

Core Viewpoint - Lyra Therapeutics is set to present 52-week results from the ENLIGHTEN 1 Phase 3 study for LYR-210, a treatment for chronic rhinosinusitis (CRS), at the COSM 2025 conference [1][2] Group 1: Product Overview - LYR-210 is a bioabsorbable nasal implant designed to deliver six months of continuous anti-inflammatory therapy using mometasone furoate for CRS patients who have failed current therapies [3][4] - The ENLIGHTEN program includes two pivotal Phase 3 clinical trials, ENLIGHTEN 1 and ENLIGHTEN 2, with approximately 180 CRS patients enrolled in each trial [2][4] Group 2: Clinical Trial Results - Results from the ENLIGHTEN 1 Phase 3 Extension Stage indicate a favorable safety profile for LYR-210, consistent with the Primary Study Phase [5][6] - In the subgroup of CRS patients with nasal polyps, improvements were observed in both symptoms and polyp size among those who crossed over from the sham group to receive LYR-210 [5][6] Group 3: Upcoming Events - The poster presentation for LYR-210 is scheduled for May 16 and 17, 2025, at the COSM 2025 conference in New Orleans [6]

Core Insights - Markel Insurance has launched a Clinical Trials insurance product to support clinical trials research and product development globally [1][5] - The new offering provides comprehensive coverage for sponsors, researchers, and participants across all phases of clinical research, tailored to meet regulatory requirements in over 100 territories [1][2] Group 1: Product Features - The Clinical Trials insurance product ensures timely issuance of quotations and policy documents through an automated platform, facilitating compliance with regulatory deadlines [2] - Markel's solution is designed to prevent delays in the clinical research process, which can lead to significant costs and reputational damage [3][4] Group 2: Industry Commitment - Markel aims to support innovation in the life sciences sector by providing effective risk transfer solutions for future lifesaving treatments [5] - The company emphasizes a people-first approach, leveraging relationships with brokers and clients to differentiate itself in the specialty insurance market [5]

Supernus Pharmaceuticals (SUPN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Peter Vozzo - Managing DirectorJack Khattar - CEO, President & DirectorTimothy Dec - Senior VP & CFOJack Padovano - Equity Research Associate - BioPharma Conference Call Participants None - AnalystStacy Ku - AnalystDavid Amsellem - Sr. Research Analyst Operator Good afternoon, and welcome to Supernus Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all particip ...

- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to support execut ...

X4 Pharmaceuticals (XFOR) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Please stand by. Your program is about to begin. Greetings, and welcome to the X4 Pharmaceuticals First Quarter twenty twenty five Financial and Operating Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Dan Ferry from LifeSci A ...

Seagen (SGEN) 2020 Conference April 29, 2025 04:10 PM ET Speaker0 Great. Welcome to the BofA Virtual Vegas Healthcare Conference. I'm Jeff Meacham. I'm the senior biopharma analyst. And Greg Harrison from my team is on with me as well. So we're thrilled to have Seattle Genetics. Speaking on behalf of Seattle is CFO, Todd Simpson. Todd, you there? Speaker1 Yep. Good morning. Speaker0 Okay, great. So the format for today, I'll ask Todd to say a couple of things to kick it off background wise, and then we've g ...